Market capitalization | $2.56b |
Enterprise Value | $2.12b |
P/E (TTM) P/E ratio | 18.32 |
EV/FCF (TTM) EV/FCF | 11.28 |
EV/Sales (TTM) EV/Sales | 4.61 |
P/S ratio (TTM) P/S ratio | 5.56 |
P/B ratio (TTM) P/B ratio | 3.87 |
Revenue growth (TTM) Revenue growth | 32.17% |
Revenue (TTM) Revenue | $460.48m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Catalyst Pharmaceuticals, Inc. forecast:
8 Analysts have issued a Catalyst Pharmaceuticals, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 460 460 |
32%
32%
|
|
Gross Profit | 360 360 |
30%
30%
|
|
EBITDA | 212 212 |
111%
111%
|
EBIT (Operating Income) EBIT | 174 174 |
129%
129%
|
Net Profit | 143 143 |
130%
130%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Catalyst Pharmaceuticals is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.
Head office | United States |
CEO | Richard Daly |
Employees | 167 |
Founded | 2002 |
Website | www.catalystpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.